Redcare Pharmacy Shares Hit Record Low Despite Surging Prescription Revenue

Redcare Pharmacy's stock hits a historic low despite record €1.07B prescription revenue in 2025, as market focuses on slowing OTC growth and margin pressures.

The stock of Redcare Pharmacy, a leading European online pharmacy, is trading at a historic low. This comes in stark contrast to its operational performance for 2025, which saw the company surpass one billion euros in prescription revenue for the first time. The market's persistent skepticism highlights a critical divergence between top-line growth and underlying profitability concerns.

Operational Strength Meets Market Skepticism

Redcare's total revenue for 2025 climbed by 24.1 percent to reach 2.9 billion euros. This growth was powered by its prescription (Rx) business, which soared 42.6 percent to 1.07 billion euros, decisively breaking the billion-euro barrier. A key driver was the accelerated rollout of Germany's e-prescription system, which helped nearly double the company's domestic Rx revenue to 503 million euros.

On a profitability basis, the company's adjusted EBITDA jumped 72 percent to 57.4 million euros, with the corresponding margin improving to 2.0 percent. However, a sequential decline in that margin to 1.6 percent in the fourth quarter—down from 2.6 percent in Q2 and 2.4 percent in Q3—signals emerging pressures.

The Over-the-Counter Slowdown

The core issue for investors lies in the performance of Redcare's higher-margin over-the-counter (OTC) segment. Growth in this business line slowed markedly to 9.3 percent in the final quarter, a significant deceleration from the 19.7 percent pace seen at the start of the year. Quarterly OTC revenue missed consensus estimates by approximately nine percent. Management cited a combination of reduced marketing spend and a challenging broader market environment for the weakness, which is weighing heavily on overall earnings potential.

Regulatory Tailwinds and Logistics Expansion

Looking ahead to 2026, Redcare's leadership has provided guidance forecasting revenue growth of 13 to 15 percent. They anticipate German Rx revenue will exceed 670 million euros, with an adjusted EBITDA margin of at least 2.5 percent. OTC growth is projected to recover to a range of 8 to 10 percent.

The regulatory landscape may offer further support. Federal Health Minister Nina Warken has announced plans to potentially increase the fixed reimbursement fee for e-prescriptions to 9.50 euros. Redcare emphasizes that every additional cent in the Rx segment flows almost directly to its bottom line. This potential boost is complemented by a recent Federal Court of Justice ruling that further opens the online market for prescription medicines.

Concurrently, the company is expanding its operational capacity. A new fulfillment center in Plze?, Czech Republic, is expected to increase annual shipping capacity for OTC products by up to 15 million parcels. The facility is also designed to improve cost efficiency through optimized delivery routes.

A Critical Test Looms

Currently, Redcare's share price trades roughly 45 percent below its 200-day moving average, a technical indicator that reflects deep investor doubt about its earnings trajectory. The company faces a crucial milestone on May 6, 2026, when it reports first-quarter results. This update will serve as the first concrete test of whether the prescription momentum can be sustained, the OTC business has stabilized, and the company's margin targets for the full year remain achievable.